Tumor-inhibiting Ruthenium Complexes
Tumor-inhibiting Ruthenium Complexes
Disciplines
Chemistry (100%)
Keywords
-
RUTHENIUM COMPOUNDS,
TUMOR-INHIBITING AGENTS,
DRUG DESIGN,
COORDINATION CHEMISTRY,
RU(III)- RU(II)-COMPLEXES,
PLASMA PROTEINS
Ruthenium complexes show promising antitumor activity in clinically relevant tumor models. Some of the ruthenium complexes to be investigated exhibit excellent activity especially in a colorectal tumor model that resembles human colon tumors in its histological appearance and behaviour against chemotherapeutics. The aim of this project will be the synthesis of new derivatives of these complexes with improved solubility in water to enable clinical trials with the compounds. Furthermore, the stability of the complexes and their hydrolysis reactions, as well as their subsequent reactions with biologically occuring targets, like plasma proteins and DNA, should be investigated. The results should lead to a deeper understanding of the mode of action of this new class of antitumor agents.
- Universität Wien - 100%
- Thomas Pieper, Universität Wien , associated research partner
- Axel Hanauske, Katholieke Universiteit Leuven - Belgium
- Viktor Brabec, Academy of Sciences of the Czech Republic - Czechia
- Ryszard Lobinski, Universite de Pau et des Pays de l´Adour - France
- Heinz-Herbert Fiebig, Albert-Ludwigs-Universität Freiburg - Germany
- Mauro Collucia, University of Bari - Italy
- Jan Reedijk, Universiteit Leiden - Netherlands
- Peter J. Sadler, University of Warwick
Research Output
- 187 Citations
- 1 Publications
-
2004
Title Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS , ESI-MS and CD spectroscopy DOI 10.1039/b309160k Type Journal Article Author Pongratz M Journal Journal of Analytical Atomic Spectrometry Pages 46-51